Akebia Therapeutics
Clinical trials sponsored by Akebia Therapeutics, explained in plain language.
Biopharmaceutical company focused on kidney disease treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug AKB-9090 takes first steps in human safety trial Results expected Dec 2026 (estimated)
- New hope for FSGS: experimental drug enters Mid-Stage trial Results expected Jun 2027 (estimated)
-
Kidney anemia pill for kids pulled before starting
Disease control CancelledThis study planned to test a daily pill called vadadustat for anemia in children with chronic kidney disease. It aimed to see if the pill could safely replace standard injections. However, the trial was withdrawn before enrolling any participants, so no results are available.
Phase 3 • Sponsor: Akebia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Kidney anemia pill study for kids pulled before it started
Disease control CancelledThis study was designed to test a once-daily pill called vadadustat for treating anemia in children with chronic kidney disease. The goal was to see if the drug could safely raise red blood cell levels without the need for injections. However, the study was withdrawn before enrol…
Phase 3 • Sponsor: Akebia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC